Cullinan Oncology Shares Present Significant Upside, Analysts Assert
Published on 12/07/2025 at 03:00 | Redaktion boerse-global.de
Market analysts are projecting substantial growth potential for Cullinan Oncology LLC (CLNN), with a consensus price target suggesting a potential gain of approximately 155% from its current trading level near $11. This optimistic outlook follows a key regulatory milestone achieved by the clinical-stage biopharmaceutical company this month.
The foundation for this bullish sentiment was solidified on December 2, when the U.S. Food and Drug Administration (FDA) granted Fast Track designation to the company’s drug candidate, CLN-049. This therapeutic is a FLT3-targeted T-cell activator being developed for patients with relapsed or refractory acute myeloid leukemia (R/R AML), an area representing a significant unmet medical need. The regulatory status is designed to facilitate Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
